ClinicalTrials.gg
CompletedNCT00568334Updated Jun 8, 2018Results posted

Study of Two Formulations of GSK Biologicals' Varicella Vaccine

A Phase 2 interventional study of Varilrix (inactivated varicella vaccine) in Varicella, sponsored by GlaxoSmithKline. Completed at 13 sites in 2 countries. Open to participants aged 11 Months to 21 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-06-08.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
244
Allocation
Randomized
Ages
11 Months to 21 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies in Chickenpox by GlaxoSmithKline — 6 open to participants now, 6 under way, 6 of them phase 3. Chickenpox · GlaxoSmithKline.

Enrollment
25th of 29
244 · median 600
Started
2007
with 5 others
Phase 2
11 of 35
none open now
Registered
15th of 35
by date

Among the 35 studies in Chickenpox by GlaxoSmithKline, this one is the 25th largest by enrollment of the 29 interventional ones that give a count, is one of 6 that started in 2007, is one of 11 in phase 2, and was the 15th registered.

Chickenpox

180 studies on the registry are indexed under Chickenpox; 28 are open to participants now.

Browse Chickenpox studies →

Open to participants now

6 of the 35 studies in Chickenpox by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 16 Chickenpox studies recruiting now, 3 (19%) set no upper age limit and 13 (81%) stop at 75 or younger; 12 take children under 18; 13 take healthy volunteers.

This study: 11 Months to 21 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Chickenpox by GlaxoSmithKline, or all of them as a file.
02

Study summary

The aim of this study is to evaluate a modified formulation of GSK Biologicals' live attenuated varicella vaccine. In vivo pre-clinical data show this change has no negative impact on vaccine safety. This present study is undertaken to rule out any negative impact on the immunogenicity and safety of GSK Biologicals' live attenuated varicella virus vaccine.

03

Conditions studied

  • Varicella

Browse trials for

Keywords

  • chickenpox
  • varicella
  • two-dose schedule
  • second year of life
04

Who can participate

Ages eligible
11 Months to 21 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits) should be enrolled in the study.
  • A male or female between, and including, 11 and 21 months of age at the time of the first vaccination.
  • Written obtained from the parent or guardian of the subject.
  • Healthy subjects as established by medical history and clinical examination before entering into the study.

Exclusion criteria

Exclusion Criteria:

  • Use of any or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
  • Chronic administration of or other immune-modifying drugs within six months prior to the first vaccine dose.
  • Planned administration/ administration of a vaccine not foreseen by the study protocol within 30 days prior to the first study vaccine dose until 42 days after second study vaccine dose with the exception of oral polio vaccine (OPV) which can be given at any time and routine inactivated vaccines which can be administered up to eight days before each study vaccine dose.
  • Previous vaccination against varicella.
  • Known history of clinical varicella.
  • Known exposure to varicella within 30 days prior to study start.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
  • A family history of congenital or hereditary immunodeficiency.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine(s), including systemic to neomycin.
  • Major congenital defects or serious chronic illness.
  • Acute disease at the time of enrolment. All vaccines can be administered to persons with a minor illness.
  • Axillary temperature ≥ 37.5°C / Rectal temperature ≥ 38°C.
  • Residence in the same household as a high risk person e.g.: new-born infants (0-4 weeks of age), pregnant women who have a negative history of chickenpox, persons with known immunodeficiency
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
244 participants (actual)

Study arms

  • Experimental
    VARILRIX HSA-FREE GROUP

    Healthy male or female children between, and including, 11 and 21 months of age, who received 2 doses of Varilrix™ vaccine produced without human serum albumin (HSA-Free), administered subcutaneously into the deltoid region of the left upper arm, at Day 0 and Day 43-57 (Week 6).

    Biological: Varilrix (inactivated varicella vaccine)

  • Experimental
    VARILRIX GROUP

    Healthy male or female children between, and including, 11 and 21 months of age, who received 2 doses of Varilrix™ vaccine, administered subcutaneously into the deltoid region of the left upper arm, at Day 0 and Day 43-57 (Week 6).

    Biological: Varilrix (inactivated varicella vaccine)

Interventions

  • BiologicalVarilrix (inactivated varicella vaccine)

    subcutaneously injection

06

What researchers measure

Primary outcomes

  1. Antibody Titers Against Varicella Zoster Virus (VZV)

    Antibody titers have been assessed by immunofluorescence assay (IFA) and presented as geometric mean titers (GMTs), for initially seronegative subjects \[with anti-VZV titer below (\<) 1:4\].

    Time frame: At 43-57 days after the first vaccine dose (Week 6)

  2. Antibody Concentrations Against Varicella Zoster Virus (VZV)

    Antibody concentrations have been assessed by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL), for initially seronegative subjects \[with anti-VZV concentration below (\<) 25 mIU/mL\].

    Time frame: At 43-57 days after the first vaccine dose (Week 6)

Secondary outcomes

  1. Number of Seroconverted Subjects for Varicella Antibodies

    Seroconversion/seroresponse (considering the IFA data) was defined as the appearance of anti-VZV antibodies \[i.e. titer/concentration greater than or equal to (≥) the assay cut-off value of 1:4\] in the sera of subjects who were seronegative before vaccination.

    Time frame: At 43-57 days post-Dose 1 (Week 6) and 86-114 days post-Dose 2 (Week 12)

  2. Number of Subjects With Anti-VZV Antibody Concentrations Above Cut-off Values

    Anti-VZV antibody concentrations greater than or equal to (≥) the assay cut-off values of: 25 mIU/mL, 50 mIU/mL and 75 mIU/mL have been assesssed by ELISA, in the sera of subjects who were seronegative before vaccination.

    Time frame: At 43-57 days post-Dose 1 (Week 6) and 86-114 days post-Dose 2 (Week 12)

  3. Antibody Titers Against Varicella Zoster Virus (VZV)

    Antibody titers have been assessed by immunofluorescence assay (IFA) and presented as geometric mean titers (GMTs), for initially seronegative subjects \[with anti-VZV titer below (\<) 1:4\].

    Time frame: At 86-114 days after the second vaccine dose (Week 12)

  4. Antibody Concentrations Against Varicella Zoster Virus (VZV)

    Antibody concentrations have been assessed by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL), for initially seronegative subjects \[with anti-VZV concentration below (\<) 25 mIU/mL\].

    Time frame: At 86-114 days after the second vaccine dose (Week 12)

  5. Number of Subjects With Any and Grade 3 Solicited Local Symptoms

    Assessed solicited local symptoms were pain, redness and swelling. Any = incidence of a particular symptom regardless of intensity grade. Grade 3 pain = cried when limb was moved/spontaneously painful. Grade 3 redness/swelling = redness/swelling spreading beyond 20 millimeters (mm) of injection site.

    Time frame: During the 4-day (Days 0-3) post-vaccination period following each dose

  6. Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms

    Assessed solicited general symptoms were fever \[defined as axillary fever ≥ 37.5 degrees Celsius (°C)\] and generalized rash. Any = occurrence of the symptom regardless of intensity grade or relationship to vaccination. Grade 3 fever = temperature above (\>) 39.0°C after vaccination. Grade 3 rash = more than (\>) 150 lesions. Related = considered by the investigator to be causally related to the study vaccination.

    Time frame: During the 43-day (Days 0-42) post-vaccination period following each dose

  7. Number of Subjects With Any Unsolicited Adverse Event (AE)

    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any was defined as an adverse event (AE) reported in addition to those solicited during the clinical study. Any solicited symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event.

    Time frame: Within the 43-day (Days 0-42) post-vaccination period following each dose

  8. Number of Subjects With Serious Adverse Events (SAEs)

    Serious adverse events (SAEs) assessed include medical occurrences that results in death, are life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject.

    Time frame: From Day 0 up to study end (Day 86-114)

07

Results

Posted Jun 28, 2017

Participant flow

Participant flow — Overall Study
MilestoneVarilrix HSA-Free GroupVarilrix Group
Started122122
Completed121121
Not completed11
Withdrew: Withdrawal by subject01
Withdrew: Lost to follow-up10

Outcome measures

PrimaryAntibody Titers Against Varicella Zoster Virus (VZV)

Antibody titers have been assessed by immunofluorescence assay (IFA) and presented as geometric mean titers (GMTs), for initially seronegative subjects \[with anti-VZV titer below (\<) 1:4\].

Time frame:
At 43-57 days after the first vaccine dose (Week 6)
Reported as:
Geometric mean · Titers
Antibody Titers Against Varicella Zoster Virus (VZV)
TitersVarilrix HSA-Free GroupVarilrix Group
Antibody Titers Against Varicella Zoster Virus (VZV)172.6 (141.6 to 210.3)154.3 (128.7 to 185)
Statistical analysis
  • Varilrix HSA-Free Group vs Varilrix Group · ANOVA · Gmt ratio: 1.12 · 95% CI 0.86 to 1.46
PrimaryAntibody Concentrations Against Varicella Zoster Virus (VZV)

Antibody concentrations have been assessed by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL), for initially seronegative subjects \[with anti-VZV concentration below (\<) 25 mIU/mL\].

Time frame:
At 43-57 days after the first vaccine dose (Week 6)
Reported as:
Geometric mean · mIU/mL
Antibody Concentrations Against Varicella Zoster Virus (VZV)
mIU/mLVarilrix HSA-Free GroupVarilrix Group
Antibody Concentrations Against Varicella Zoster Virus (VZV)123.5 (107.9 to 141.4)110.7 (98.4 to 124.6)
Statistical analysis
  • Varilrix HSA-Free Group vs Varilrix Group · ANOVA · Gmc ratio: 1.12 · 95% CI 0.93 to 1.33
SecondaryNumber of Seroconverted Subjects for Varicella Antibodies

Seroconversion/seroresponse (considering the IFA data) was defined as the appearance of anti-VZV antibodies \[i.e. titer/concentration greater than or equal to (≥) the assay cut-off value of 1:4\] in the sera of subjects who were seronegative before vaccination.

Time frame:
At 43-57 days post-Dose 1 (Week 6) and 86-114 days post-Dose 2 (Week 12)
Reported as:
Count of participants · Participants
Number of Seroconverted Subjects for Varicella Antibodies
ParticipantsVarilrix HSA-Free GroupVarilrix Group
Anti-VZV, Week 6114114
Anti-VZV, Week 12115112
SecondaryNumber of Subjects With Anti-VZV Antibody Concentrations Above Cut-off Values

Anti-VZV antibody concentrations greater than or equal to (≥) the assay cut-off values of: 25 mIU/mL, 50 mIU/mL and 75 mIU/mL have been assesssed by ELISA, in the sera of subjects who were seronegative before vaccination.

Time frame:
At 43-57 days post-Dose 1 (Week 6) and 86-114 days post-Dose 2 (Week 12)
Reported as:
Count of participants · Participants
Number of Subjects With Anti-VZV Antibody Concentrations Above Cut-off Values
ParticipantsVarilrix HSA-Free GroupVarilrix Group
Anti-VZV ≥ 25 mIU/mL, Week 6114113
Anti-VZV ≥ 25 mIU/mL, Week 12116114
Anti-VZV ≥ 50 mIU/mL, Week 6105103
Anti-VZV ≥ 50 mIU/mL, Week 12116114
Anti-VZV ≥ 75 mIU/mL, Week 68989
Anti-VZV ≥ 75 mIU/mL, Week 12116114
SecondaryAntibody Titers Against Varicella Zoster Virus (VZV)

Antibody titers have been assessed by immunofluorescence assay (IFA) and presented as geometric mean titers (GMTs), for initially seronegative subjects \[with anti-VZV titer below (\<) 1:4\].

Time frame:
At 86-114 days after the second vaccine dose (Week 12)
Reported as:
Geometric mean · Titers
Antibody Titers Against Varicella Zoster Virus (VZV)
TitersVarilrix HSA-Free GroupVarilrix Group
Antibody Titers Against Varicella Zoster Virus (VZV)1452.5 (1240.7 to 1700.5)1395.4 (1183 to 1645.9)
SecondaryAntibody Concentrations Against Varicella Zoster Virus (VZV)

Antibody concentrations have been assessed by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL), for initially seronegative subjects \[with anti-VZV concentration below (\<) 25 mIU/mL\].

Time frame:
At 86-114 days after the second vaccine dose (Week 12)
Reported as:
Geometric mean · mIU/mL
Antibody Concentrations Against Varicella Zoster Virus (VZV)
mIU/mLVarilrix HSA-Free GroupVarilrix Group
Antibody Concentrations Against Varicella Zoster Virus (VZV)1013.6 (880.9 to 1166.4)999.2 (877.3 to 1138.1)
SecondaryNumber of Subjects With Any and Grade 3 Solicited Local Symptoms

Assessed solicited local symptoms were pain, redness and swelling. Any = incidence of a particular symptom regardless of intensity grade. Grade 3 pain = cried when limb was moved/spontaneously painful. Grade 3 redness/swelling = redness/swelling spreading beyond 20 millimeters (mm) of injection site.

Time frame:
During the 4-day (Days 0-3) post-vaccination period following each dose
Reported as:
Count of participants · Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
ParticipantsVarilrix HSA-Free GroupVarilrix Group
Any Pain, Dose 11315
Grade 3 Pain, Dose 100
Any Redness, Dose 13334
Grade 3 Redness, Dose 100
Any Swelling, Dose 157
Grade 3 Swelling, Dose 100
Any Pain, Dose 22318
Grade 3 Pain, Dose 200
Any Redness, Dose 24446
Grade 3 Redness, Dose 263
Any Swelling, Dose 21814
Grade 3 Swelling, Dose 222
SecondaryNumber of Subjects With Any, Grade 3 and Related Solicited General Symptoms

Assessed solicited general symptoms were fever \[defined as axillary fever ≥ 37.5 degrees Celsius (°C)\] and generalized rash. Any = occurrence of the symptom regardless of intensity grade or relationship to vaccination. Grade 3 fever = temperature above (\>) 39.0°C after vaccination. Grade 3 rash = more than (\>) 150 lesions. Related = considered by the investigator to be causally related to the study vaccination.

Time frame:
During the 43-day (Days 0-42) post-vaccination period following each dose
Reported as:
Count of participants · Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
ParticipantsVarilrix HSA-Free GroupVarilrix Group
Any Temperature, Dose 16452
Grade 3 Temperature, Dose 11311
Related Temperature, Dose 122
Any Rash, Dose 110
Grade 3 Rash, Dose 15453
Related Rash, Dose 1612
Any Temperature, Dose 233
Grade 3 Temperature, Dose 210
Related Temperature, Dose 23118
Any Rash, Dose 200
Grade 3 Rash, Dose 23123
Related Rash, Dose 210
SecondaryNumber of Subjects With Any Unsolicited Adverse Event (AE)

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any was defined as an adverse event (AE) reported in addition to those solicited during the clinical study. Any solicited symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event.

Time frame:
Within the 43-day (Days 0-42) post-vaccination period following each dose
Reported as:
Count of participants · Participants
Number of Subjects With Any Unsolicited Adverse Event (AE)
ParticipantsVarilrix HSA-Free GroupVarilrix Group
Any AE(s), Dose 15645
Any AE(s), Dose 23542
SecondaryNumber of Subjects With Serious Adverse Events (SAEs)

Serious adverse events (SAEs) assessed include medical occurrences that results in death, are life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject.

Time frame:
From Day 0 up to study end (Day 86-114)
Reported as:
Count of participants · Participants
Number of Subjects With Serious Adverse Events (SAEs)
ParticipantsVarilrix HSA-Free GroupVarilrix Group
Number of Subjects With Serious Adverse Events (SAEs)25

Adverse events

Collected over Solicited local symptoms: during the 4-day (Days 0-3) post each dose. Solicited general symptoms and unsolicited AEs: during the 43-day (Days 0-42) post each dose. SAEs: during the entire study period (Day 0 to Day 86/114).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Varilrix HSA-Free Group0/122 (0%)2/122 (1.6%)103/122 (84.4%)
Varilrix Group0/122 (0%)5/122 (4.1%)100/122 (82%)
Most frequent serious events
Most frequent serious events
EventVarilrix HSA-Free GroupVarilrix Group
ConcussionInjury, poisoning and procedural complications0/1221/122
Breath holdingPsychiatric disorders0/1221/122
Otitis mediaInfections and infestations1/1221/122
BronchitisInfections and infestations0/1221/122
GastroenteritisInfections and infestations1/1220/122
LaryngitisInfections and infestations0/1221/122
MastoiditisInfections and infestations0/1221/122
SinusitisInfections and infestations0/1221/122
Most frequent other events
Showing 10 of 14
Most frequent other events
EventVarilrix HSA-Free GroupVarilrix Group
Fever (Dose 1)General disorders64/12152/122
Fever (Dose 2)General disorders54/12153/121
Redness (Dose 2)General disorders44/12146/121
Redness (Dose 1)General disorders33/12134/122
Pain (Dose 2)General disorders23/12118/121
Swelling (Dose 2)General disorders18/12114/121
Pain (Dose 1)General disorders13/12115/122
Bronchitis (Dose 1)Infections and infestations15/1228/122
Viral infection (Dose 2)Infections and infestations6/12113/121
Bronchitis (Dose 2)Infections and infestations8/12111/121

Baseline characteristics

Age, Continuous
Age, Continuous(Months)Varilrix HSA-Free GroupVarilrix GroupTotal
Mean15.6 ± 3.3414.8 ± 3.0815.20 ± 3.23
Sex: Female, Male
Sex: Female, Male(Participants)Varilrix HSA-Free GroupVarilrix GroupTotal
Female5960119
Male6362125
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Varilrix HSA-Free GroupVarilrix GroupTotal
White-Caucasian/European heritage122122244
08

Study locations

13 sites
  • GSK Investigational Site
    Nachod, 547 01, Czechia
  • GSK Investigational Site
    Pardubice, 532 03, Czechia
  • GSK Investigational Site
    Bordány, 6795, Hungary
  • GSK Investigational Site
    Budapest, 1032, Hungary
  • GSK Investigational Site
    Budapest, 1040, Hungary
  • GSK Investigational Site
    Budapest, 1097, Hungary
  • GSK Investigational Site
    Budapest, 1121, Hungary
  • GSK Investigational Site
    Győr, 9024, Hungary
  • GSK Investigational Site
    Miskolc, 3524, Hungary
  • GSK Investigational Site
    Miskolc, 3528, Hungary
  • GSK Investigational Site
    Miskolc, 3543, Hungary
  • GSK Investigational Site
    Szeged, 6723, Hungary
  • GSK Investigational Site
    Zsombó, 6792, Hungary
09

References and documents

Publications

  • Prymula R, Simko R, Povey M, Kulcsar A. Varicella vaccine without human serum albumin versus licensed varicella vaccine in children during the second year of life: a randomized, double-blind, non-inferiority trial. BMC Pediatr. 2016 Jan 13;16:7. doi: 10.1186/s12887-016-0546-5. PubMed 26762528 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2007 to primary completion in Mar 2008, 4 months.

Results were first posted in Jun 2017, 9 years 3 months after primary completion.

Of 17 phase 2 interventional studies under Chickenpox, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 38. This study's 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2007
First posted
Dec 6, 2007
StartActual
Nov 1, 2007
Primary completionActual
Mar 18, 2008
CompletionActual
Apr 29, 2008
Results first posted
Jun 28, 2017
Last update
Jun 8, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00568334
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Dec 6, 2007
Start date
Nov 1, 2007
Primary completion
Mar 18, 2008
Completion
Apr 29, 2008
Results posted
Jun 28, 2017
Last update
Jun 8, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion